Skip to content
Biodatica
Start free

German CLL Study Group

Innsbruck

OncologyPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

2mo agoTrial registeredApr 30, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Momentum 76 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Apr 2, 2026

    Chronic Lymphocytic Leukemia · RECRUITING · sponsor: German CLL Study Group · A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

    ClinicalTrials.gov · NCT06792994 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Apr 19, 2022

    Chronic Lymphocytic Leukemia · RECRUITING · sponsor: German CLL Study Group · A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

    ClinicalTrials.gov · NCT05197192 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jun 1, 2021

    Chronic Lymphoid Leukemia · COMPLETED · sponsor: German CLL Study Group · Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

    ClinicalTrials.gov · NCT04883749 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources